Rilimogene galvacirepvec-rilimogene glafolivec

加-瑞利莫近-rilimogene glafolivec

Report date: 2025/01/15 11:09:30

Base Information

Drug NameRilimogene galvacirepvec-rilimogene glafolivec
Drug Alias Name加伐瑞莫基-rilimogene glafolivecrilimogenum galvacirepvecumVaccinia PSA TRICOM-fowlpox PSA TRICOMRilimogene gamvacirepvec-rilimogene glafolivecRilimogene-glafolivec-rilimogene-galvacirepvec +[17] 
ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsProstatic NeoplasmsAdenocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesMedical University Of South CarolinaBavarian Nordic A/S
Active IndicationsProstatic NeoplasmsAdenocarcinoma
Inactive IndicationsHormone-Resistant Prostate Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia